CoChat

Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Open access

Published version of a preprint

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combined with cetuximab, in patients with progressive disease (PD) on anti-EGFR treatment. Patients and Methods: Twenty-one patients with quadruple-wild-type, refractory mCRC enrolled in this 3+3 phase Ib study. Standard dosage cetuximab was administered with neratinib at 120 mg, 160 mg, 200 mg, and 240 mg/day orally in 28-day cycles. Samples were collected for molecular and pharmacokinetic studies. Results: Sixteen patients were evaluable for dose-limiting toxicity (DLT). 240 mg was determined to be the RP2D wherein a single DLT occurred (1/7 patients). Treatment-related DLTs were not seen at lower doses. Best response was stable disease (SD) in 7 of 16 (44%) patients. HER2 amplification (chromogenic in situ IHC) was detected in 2 of 21 (9.5%) treatment-naïve tumors and 4 of 16 (25%) biopsies upon trial enrollment (post-anti-EGFR treatment and progression). Compared with matched enrollment biopsies, 6 of 8 (75%) blood samples showed concordance for HER2 CNV in circulating cell-free DNA. Five SD patients had HER2 amplification in either treatment-naïve or enrollment biopsies. Examination of gene-expression, total protein, and protein phosphorylation levels showed relative upregulation of ≥2 members of the HER-family receptors or ligands upon enrollment versus matched treatment-naïve samples. Conclusions: The RP2D of neratinib in this combination was 240 mg/day, which was well tolerated with low incidence of G3 AEs. There were no objective responses; SD was seen at all neratinib doses. HER2 amplification, detectable in both tissue and blood, was more frequent post-anti-EGFR therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-1831

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 27

Metadata

Authors
Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., Gavin, P. G., Lipchik, C., Feng, H., Wang, Y., Finnigan, M., Kiesel, B. F., Beumer, J. H., Wolmark, N., Lucas, P. C., Allegra, C. J., & Srinivasan, A.
Affiliations
  • NSABP Foundation (US)
  • UPMC Health System (US)
  • University of Florida (US)
  • Cancer Care Specialists of Illinois (US)
  • Trinity Health Michigan (US)
  • Henry Ford Health (US)
  • Thomas Jefferson University (US)
  • International Drug Development Institute (Belgium) (BE)
  • 1NSABP Foundation, Inc., Pittsburgh, Pennsylvania.
  • University of Pittsburgh (US)
Corresponding author
  • Jacobs, Samuel A.
  • Srinivasan, Ashok
Venue
Clinical Cancer Research
Published
2020-11-17
Volume
27
Issue
6
Pages
1612-1622
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3098653729
Cited by
27
References
42
Citations by year
2026: 4 · 2025: 4 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 1
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
NCI (P30 CA047904, R50 CA211241)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
neratinib, cetuximab, metastatic colorectal cancer, HER2 amplification, anti-EGFR therapy resistance, recommended phase 2 dose, dose-limiting toxicity, cell-free DNA, anti-EGFR therapy, combination therapy
MeSH terms
Cetuximab, Panitumumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Male, Membrane Proteins, Middle Aged, Mutation, Neoplasm Metastasis, Prognosis, Quinolines, Retrospective Studies, Tissue Distribution, Biomarkers, Tumor, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, GTP Phosphohydrolases, Maximum Tolerated Dose, Proto-Oncogene Proteins B-raf, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1831
The paper
Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., Gavin, P. G., Lipchik, C., Feng, H., Wang, Y., Finnigan, M., Kiesel, B. F., Beumer, J. H., Wolmark, N., Lucas, P. C., . . . Srinivasan, A. (2021). Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1831

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.